Search Results

You are looking at 81 - 90 of 840 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Robert J. Motzer, Eric Jonasch, Shawna Boyle, Maria I. Carlo, Brandon Manley, Neeraj Agarwal, Ajjai Alva, Katy Beckermann, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Christos Kyriakopoulos, Elaine T. Lam, Clayton Lau, Bryan Lewis, David C. Madoff, Brittany McCreery, M. Dror Michaelson, Amir Mortazavi, Lakshminarayanan Nandagopal, Phillip M. Pierorazio, Elizabeth R. Plimack, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L. Smith, Bradley Somer, Jeffrey Sosman, Mary A. Dwyer, and Angela D. Motter

nonmetastatic primary RCC typically consists of surgery (ie, nephrectomy). Systemic therapy options for patients with relapsed or stage IV disease include kinase inhibitors, mTOR inhibitors, and monoclonal antibodies against VEGF, PD-1, or PD-L1. Recommended

Full access

Resistance to Imatinib: Mechanisms and Management

Michael Deininger

) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL) [abstract] . Blood. 2004 ; 104 : 10a . 48 Gumireddy K Baker SJ Cosenza SC . A non

Full access

NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven De Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

targeted therapies, such as BTK inhibitors, PI3K inhibitors, EZH2 inhibitors, antibody–drug conjugates, anti-CD19 CAR T-cell therapies, and other CD19-directed targeted therapies, have emerged as effective treatment options for relapsed/refractory (R

Full access

Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

Mathias Rummel

, many randomized studies indicate that combining rituximab with chemotherapy provides a substantial benefit compared with chemotherapy alone, in both the front-line and relapsed/refractory settings. 14 , 15 In a meta-analysis of patients with newly

Full access

Biologic Agents in the Management of Hodgkin Lymphoma

Armin Rashidi and Nancy L. Bartlett

patients with newly diagnosed classical Hodgkin lymphoma (HL) have an excellent prognosis after multiagent chemotherapy with or without radiation. Biologic agents offer highly desirable approaches to patients with relapsed or refractory disease in which the

Full access

Melanoma, Version 4.2014

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho

reduce nodal relapse is a source of ongoing controversy because of the lack of survival benefits and concerns of late toxicities. With the advent of targeted therapy for advanced melanoma, there is increasing appreciation that the incidence of specific

Full access

Hematopoietic Stem Cell Transplantation for Older Patients With Myelodysplastic Syndromes

H. Joachim Deeg and Marcos de Lima

-high-risk cytogenetics according to the revised IPSS-R criteria, have a very poor outcome after HCT, primarily related to relapse, which may occur in as many as 40% of patients. 26 This may be even more of an issue in older patients because of the use of RIC regimens

Full access

The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma

William I. Bensinger

the EBMT. European Group for Blood and Marrow Transplant . Br J Haematol 1998 ; 102 : 1115 – 1123 . 24 Corradini P Cavo M Lokhorst H . Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse

Full access

Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Philip L. McCarthy

: 825 – 831 . 4 Richardson PG Schlossman RL Weller E . Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma . Blood 2002 ; 100 : 3063 – 3067 . 5 Rajkumar SV

Full access

Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Ysabel Duron, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, David G. Maloney, David Mansur, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Matthew Poppe, Barbara Pro, Jane N. Winter, Joachim Yahalom, and Hema Sundar

drug conjugates (ADC) and monoclonal antibodies have shown promising results for patients with relapsed or progressive disease. 3 , 4 The following sections of these NCCN Guidelines Insights include the major discussion points from the 2011 Hodgkin